Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2
Molnupiravir is a nucleoside analog. It has shown to be able to cause mutations accumulation and the RNA replication errors during the virus replication in vitro and in mouse models (in-vivo).
Let’s look at the following
What is Molnupiravir?
What is EIDD-281?
What is a nucleoside and a nucleotide?
How is positive mRNA is replicated to a negative sense RNA and back again during the viral replication?
How does EIDD-281 disrupt this process?
Why is it better performing than Remdesivir?
It’s therapeutic dose is non cytotoxic.
Concerns about its toxicity in humans.
References
https://stm.sciencemag.org/content/12/541/eabb5883
https://en.wikipedia.org/wiki/Molnupiravir
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848974/
https://en.wikipedia.org/wiki/Nucleoside
https://en.wikipedia.org/wiki/Nucleotide
https://www.reuters.com/article/us-health-coronavirus-merck-co/merck-says-study-shows-covid-19-drug-causes-quick-reduction-in-virus-idUSKBN2AY07U
https://clinicaltrials.gov/ct2/show/NCT04405739
Merck has a new drug molecule for SARS-COV-2. It is named Molnupiravir or EIDD-2801. We will discuss the following topics about this drug.
No credit card information needed.
MD., MSc., MSc., BSc
Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.
Write A New Comment
0 Comments